Welcome to our dedicated page for Marker Therapeut SEC filings (Ticker: MRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Marker Therapeutics, Inc. (Nasdaq: MRKR), a Houston-based clinical-stage immuno-oncology company developing multi-antigen recognizing T cell (MAR-T) therapies for hematological malignancies and solid tumors. These regulatory documents offer detailed insight into the company’s financial condition, governance, and clinical and corporate milestones.
Through Marker’s periodic reports, such as annual reports on Form 10-K and quarterly reports on Form 10-Q, readers can examine financial statements, grant income from U.S. state and federal agencies, research and development spending related to programs like MT-601 and MT-401-OTS, and discussions of risks associated with clinical-stage biotechnology operations. Current reports on Form 8-K disclose material events, including clinical updates from the Phase 1 APOLLO study in relapsed lymphoma, initiation of the Off-the-Shelf MAR-T program in AML and MDS, financial results for specific quarters, changes in the company’s independent registered public accounting firm, and appointments to the board of directors.
Stock Titan enhances these filings with AI-powered summaries that explain key points in clear language, helping users interpret complex disclosures without reading every line of each document. Real-time updates from the SEC’s EDGAR system ensure that new MRKR filings, including 8-Ks describing clinical or corporate developments, are available promptly. Users can also review exhibits attached to filings, such as press releases and presentations referenced in 8-Ks, to understand how Marker communicates its MAR-T platform progress and strategic decisions.
For investors researching MRKR stock, this page offers a structured view of Marker Therapeutics’ regulatory history, from financial reporting and auditor changes to clinical trial disclosures and governance updates, with AI tools that highlight the most relevant information in each filing.
Marker Therapeutics is asking stockholders to vote at its May 1, 2026 virtual annual meeting on a broad set of governance and capital structure items. Stockholders will elect five directors, hold an advisory vote on executive pay, and ratify CBIZ as auditor for 2026.
A key proposal would amend the Certificate of Incorporation to increase authorized common stock from 30,000,000 to 130,000,000 shares, which could support future capital raising, equity incentives, or strategic transactions and may dilute existing holders if issued. Another proposal would lower the voting threshold for future changes to authorized share amounts or reverse splits to a majority of votes cast, aligning with recent Delaware law.
Stockholders will also vote on an adjournment proposal that would allow the meeting to be postponed to solicit more support for the share‑increase amendment if needed. The proxy describes board independence, committee structures, diversity, and compensation for President and CEO Juan Vera, M.D., who received $741,190 in total 2025 compensation.
Marker Therapeutics reported 2025 results and clinical progress for its MAR‑T cell therapies. The Phase 1 APOLLO study in relapsed non-Hodgkin lymphoma showed a 66% objective response rate, including 50% complete responses, with a favorable safety profile and dose expansion underway in DLBCL. The company plans another APOLLO data update in the second quarter of 2026 and is preparing a company-sponsored pancreatic cancer trial, supported by strong preclinical data published in Nature Medicine.
Financially, Marker ended December 31, 2025 with $17 million in cash, cash equivalents and restricted cash and expects this to fund operations through the fourth quarter of 2026. Grant revenue was $3.5 million, research and development expenses were $11.8 million, general and administrative expenses were $4.2 million, and net loss was $12.2 million, reflecting a modestly higher loss year over year as the pipeline advanced.
Marker Therapeutics files its annual report outlining progress on its MAR‑T cell immunotherapy pipeline and partnerships. The company is advancing MT‑601 for relapsed lymphoma (APOLLO trial) and pancreatic cancer (PANACEA), plus an off‑the‑shelf MT‑401 program for AML and MDS.
Grants from CPRIT and NIH/SBIR, including a $9.5 million CPRIT pancreatic cancer award and a $2 million NIH SBIR grant, are helping fund MT‑601 without diverting resources from lymphoma. Marker shifted manufacturing from Cell Ready to BCM and Cellipont to prepare for larger MT‑601 trials.
As of June 30, 2025, non‑affiliate equity market value was about $17.3 million, based on a $1.53 Nasdaq price. Shares outstanding were 16,673,127 as of March 16, 2026. The report also details extensive licensing, royalty, and regulatory frameworks around its MAR‑T platform.
Marker Therapeutics, Inc. is soliciting proxies for its virtual Annual Meeting of Stockholders on May 1, 2026 to vote on six proposals, including an amendment to increase authorized Common Stock from $0 (30,000,000 shares) to $0 (130,000,000 shares).
Other matters include an advisory “say-on-pay” vote, approval to align future voting thresholds with Section 242(d)(2) of the DGCL, ratification of CBIZ CPAs P.C. as independent auditors for fiscal 2026, a conditional adjournment proposal tied to Proposal 3, and director elections. The record date is March 10, 2026. The filing discloses 16,673,127 shares outstanding as of March 9, 2026.
Marker Therapeutics, Inc. has set the date for its 2026 Annual Meeting of Stockholders for May 1, 2026. This meeting date is more than 30 days earlier than the prior year’s annual meeting, which triggers updated notice requirements for shareholder proposals.
The company states that stockholder proposals intended for inclusion in the 2026 proxy statement under SEC Rule 14a-8 must be received at its Houston headquarters by March 9, 2026. The specific record date, time, and location of the meeting will be provided in the upcoming proxy statement.
Marker Therapeutics, Inc. (MRKR) disclosed that director Katharine Knobil received new stock option grants under the company's 2020 Omnibus Stock Ownership Plan. On November 17, 2025, she was granted options to buy 84,411 shares of common stock at an exercise price of $0.9548 per share for her remaining 2024 director service, in addition to 30,000 options previously granted on February 12, 2025. She also received a separate grant of stock options for 137,330 shares of common stock at the same exercise price for her 2025 director service. All of these options vest on the anniversary of the grant date and are held directly.
Marker Therapeutics, Inc. (MRKR) reported that director Norman David Eansor received new stock option awards. On 11/17/2025, he was granted options to purchase 84,411 shares of common stock at an exercise price of $0.9548 per share under the company’s 2020 Omnibus Stock Ownership Plan, representing the remaining options for his service as a director for 2024. These options vest on the anniversary of the grant date and expire on 11/17/2035.
On the same date, he was also granted options to purchase an additional 137,330 shares of common stock at an exercise price of $0.9548 per share for his service as a director for 2025. These options have the same vesting schedule and expiration date of 11/17/2035 and are held as direct ownership.
Marker Therapeutics director Steve Elms reported new stock option awards for board service. On 11/17/2025, he received stock options to buy 84,411 shares of common stock at an exercise price of $0.9548, representing remaining options for his 2024 director compensation under the 2020 Omnibus Stock Ownership Plan; 30,000 shares had previously been granted on February 12, 2025. On the same date, he also received options for 137,330 shares for his 2025 director service, also at $0.9548 per share. Both grants vest on the anniversary of the grant date and expire on 11/17/2035, and are held as direct ownership.
Marker Therapeutics filed a Form 8-K to report its financial results for the third quarter ended September 30, 2025, and to provide recent corporate updates. The company furnished a press release as Exhibit 99.1, which is incorporated by reference.
The disclosure under Item 2.02 is expressly stated as furnished and not deemed filed under the Exchange Act or Securities Act, limiting associated liabilities. The filing lists the company’s common stock trading under MRKR on The Nasdaq Stock Market and was signed by President and CEO Juan Vera.